Opinion|Videos|June 9, 2025
Safety and Efficacy Results from AGAVE-201 (Axatilimab Therapy in cGVHD)
Panelists discuss how axatilimab showed promising response rates in the AGAVE-201 trial, even in patients with graft-vs-host disease (cGVHD) who had failed other approved therapies.
Advertisement
Episodes in this series
Belumosudil and Axatilimab Data
This segment presents follow-up data from the ROCKstar study of belumosudil, showing:
- 74%-76% overall response rate across both dosing regimens (200 mg once or twice daily)
- Consistent responses across organ systems
- 57% failure-free survival at 12 months
- 25% of patients successfully discontinued all immunosuppression
- Common adverse events included fatigue, gastrointestinal symptoms, cough, and headache
The panel transitions to axatilimab data from the AGAVE-201 trial, which evaluated 3 different dosing regimens. The FDA-approved dose (0.3 mg/kg every 2 weeks) demonstrated:
- 74% overall response rate
- Median time to response of 1.4-1.7 months
- Median failure-free survival of approximately 11 months
- Main adverse events were laboratory abnormalities related to CSF1R blockade
Advertisement
Related to this article
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
4
Weighing Logistics and Time Savings of Subcutaneous Drug Delivery
5